A lot of Canadians are on a GLP-1 medication right now, or thinking about it, or know three people who are. Ozempic, Wegovy, Mounjaro: the names have become part of the national vocabulary. What gets talked about far less is what these medications do to your gut, and what a simple, unglamorous nutrient like fibre can (and can't) do about it.
This isn't a fibre-versus-medication story. It's about how the two actually work together, and where a daily fibre habit fits if you're on a GLP-1 drug, thinking about one, or just curious about the biology behind the headlines.
The GLP-1 boom, in plain terms
GLP-1 receptor agonists (semaglutide, tirzepatide, and similar drugs) mimic a hormone your gut already makes: glucagon-like peptide-1. Naturally occurring GLP-1 is released after you eat, and it does a few jobs at once. It tells your pancreas to release insulin, it slows down how fast your stomach empties, and it signals to your brain that you're full. GLP-1 medications amplify that same signal, which is a big part of why they're effective for blood sugar control and weight management.
The catch is that "slows down how fast your stomach empties" doesn't stop at the stomach. It tends to slow transit through the rest of the digestive tract too, and that's where the less-discussed side effect comes in.
Why constipation shows up so often
Constipation is one of the most consistently reported side effects of GLP-1 therapy. In the landmark STEP 1 trial published in the New England Journal of Medicine, constipation was reported in roughly a quarter of participants on semaglutide 2.4 mg, compared with about one in nine on placebo. Across the broader STEP trial program, gastrointestinal complaints, constipation included, were consistently more common in the semaglutide groups. Most cases were described as mild to moderate and did not lead people to stop the medication, but "mild to moderate" doesn't mean pleasant to live with.
The mechanism makes sense once you see it laid out: food moves more slowly through a system that's already being told to slow down, water gets reabsorbed for longer along the way, and stool becomes harder and less frequent. It's a predictable side effect of the drug doing what it's designed to do, not a sign anything has gone wrong.
Where fibre comes in
Fibre is one of the few nutrition tools that plays on both sides of the GLP-1 story: it may help with the appetite and satiety piece that draws people to these medications in the first place, and it can help manage the constipation that often comes along for the ride.
Fibre and satiety: working with the same signal
Viscous soluble fibres, the gel-forming type found in psyllium husk, slow gastric emptying in a way that overlaps with how GLP-1 itself behaves. A systematic review and meta-analysis of randomized controlled trials found that soluble fibre supplementation was associated with reduced hunger and increased fullness ratings in healthy adults, along with modestly lower energy intake at later meals. The proposed mechanisms include slower gastric emptying, increased gut viscosity that delays nutrient absorption, and stimulation of gut hormones involved in appetite regulation, including GLP-1 itself.
That last point is worth sitting with. Your gut already knows how to make its own GLP-1. When fibre ferments in the colon, it produces short-chain fatty acids (acetate, propionate, and butyrate), and research on the gut-hormone axis shows these short-chain fatty acids can stimulate the release of GLP-1 from L-cells lining the gut, the same hormone that GLP-1 medications are designed to mimic. A more recent scoping review looked specifically at dietary fibre's potential to boost endogenous GLP-1 secretion and satiety, suggesting fibre may support the body's own version of the pathway these drugs target pharmacologically. This doesn't mean fibre replaces medication, or comes close to it in magnitude. It means the two are working on overlapping biology, not competing ones.
Fibre and the constipation side effect
On the other side of the equation, fibre is one of the most well-established tools for improving stool consistency and bowel regularity in general. A recent clinical perspective piece specifically examining fibre supplementation during and after GLP-1 receptor agonist treatment notes that while dedicated trials combining fibre with GLP-1 drugs are still limited, the existing evidence on fibre and bowel function suggests it's a reasonable, low-risk strategy worth discussing with a healthcare provider if constipation becomes an issue on these medications.
Not all fibre behaves the same way here, though, which matters more on a GLP-1 medication than off one. A gut that's already moving slowly generally responds better to a gel-forming soluble fibre like psyllium, which softens and adds moisture to stool, than to large amounts of coarse insoluble fibre (think wheat bran), which can add bulk without adding water and may feel worse on a sluggish system.
The evidence, and its limits
To be direct about what the research does and doesn't show: there is strong, long-standing evidence that soluble fibre supports satiety and that it improves bowel regularity generally. There is much thinner direct evidence, so far, on fibre specifically combined with GLP-1 receptor agonist therapy. Researchers reviewing this space have flagged the combination as promising and biologically sensible, but not yet proven through large dedicated trials in people taking these medications. That's an honest gap, and it's worth knowing.
What this means practically: fibre is a reasonable, evidence-informed habit to build whether or not you're on a GLP-1 medication. It is not a substitute for the medication's effects, and anyone managing side effects on one of these drugs should loop in their doctor or pharmacist, especially before making significant changes to diet, hydration, or fibre intake.
Where this fits with Mr. Regular
Mr. Regular wasn't built around GLP-1 medications, it was built around the simple idea that most Canadians fall short on fibre and a daily drink mix is an easy way to close that gap. But the overlap is real. Mr. Regular Original is built on organic psyllium husk, the same viscous soluble fibre studied for satiety and gentle regularity. Mr. Regular Prebiotic pairs psyllium with Orafti inulin and Solnul resistant starch, fibres chosen in part because they ferment gently and feed the same short-chain fatty acid pathway discussed above, without the harsh gas and bloating that put a lot of people off fibre supplements in the first place.
If you're on a GLP-1 medication and dealing with constipation, or just trying to eat with more intention while on one, a gentle, low-dose daily fibre habit is worth raising with your care team as part of the conversation. You can read more about how we think about fibre science on our science page.
What to look for on a label
- A viscous soluble fibre first. Psyllium husk is the most studied option for both satiety and stool softening.
- A dose you can actually start low with. Titrating up slowly reduces gas and bloating, especially useful if your gut is already adjusting to a GLP-1 medication.
- No added sugar or artificial sweeteners that could work against your goals.
- Transparent fibre sourcing. Look for named ingredients (organic psyllium husk, Orafti inulin, Solnul resistant starch) rather than a vague "fibre blend."
- Realistic serving guidance that pairs fibre with adequate water, since fibre without enough fluid can make things worse, not better.
The takeaway
GLP-1 medications and dietary fibre aren't rivals. They lean on overlapping biology, the same gut hormone pathway, the same appetite signals, and fibre may help smooth out one of the most common side effects of these drugs. The evidence for fibre and satiety is well established. The evidence for fibre specifically alongside GLP-1 therapy is promising but still developing. Either way, a consistent daily fibre habit is one of the simplest, lowest-risk moves in the whole conversation, and it's one worth having with your doctor or pharmacist if you're navigating GLP-1 treatment.
References
- Wilding JPH, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine (STEP 1 trial).
- Systematic review and meta-analysis of randomised controlled trials on soluble dietary fibre, energy intake, and perceived satiety in healthy adults. PubMed Central.
- The impact of short-chain fatty acids on GLP-1 and PYY secretion from the isolated perfused rat colon. American Journal of Physiology, Gastrointestinal and Liver Physiology.
- Dietary fibers to boost endogenous GLP-1 secretion and satiety: a scoping review. Frontiers in Endocrinology.
- Fiber Supplementation during and after Glucagon-Like Peptide-1 Receptor Agonists Treatment: A Perspective on Clinical Benefits. ScienceDirect.
This article is for general education and is not medical advice. If you have ongoing health concerns or take medication, please speak with your doctor or pharmacist.